Advertisement
Singapore markets closed
  • Straits Times Index

    3,233.94
    -17.77 (-0.55%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • Dow

    39,760.08
    +477.75 (+1.22%)
     
  • Nasdaq

    16,399.52
    +83.82 (+0.51%)
     
  • Bitcoin USD

    70,601.70
    +1,066.43 (+1.53%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,956.16
    +24.18 (+0.30%)
     
  • Gold

    2,216.20
    +3.50 (+0.16%)
     
  • Crude Oil

    81.76
    +0.41 (+0.50%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,264.80
    -45.29 (-0.62%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Understanding Endo International’s Operational Performance

Understanding Endo International’s Operational Performance

How's Endo International Positioned in December? For fiscal 2018 and 2019, Endo is expected to incur research and development expenses of $162.01 million and $165.43 million, respectively. Endo expects its US generic pharmaceuticals research and development costs to decline due to its moving its R&D activities to India.